BackInsmed Overview
Insmed Inc

Insmed Target Price

Analysts' average 12-month price target for Insmed is $190.

Get informed when a big investor buys or sells

+ Follow

Share Price

$118.07

Average Target Price

$192.4063% upside

20 analysts in the last 4 months

High: $235 | Low: $154

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-11-02GuggenheimVamil Divan$20170.2% upsideOpen
2026-10-29Stifel NicolausStephen Willey$19565.2% upsideOpen
2026-10-29Mizuho Securities$15430.4% upsideOpen
2026-10-21Morgan Stanley$21380.4% upsideOpen
2026-10-20Raymond James$17346.5% upsideOpen
2026-10-12Raymond James$20775.3% upsideOpen
2026-09-30Barclays$20775.3% upsideOpen
2026-09-24Goldman Sachs$18859.2% upsideOpen
2026-09-15Roth CapitalAdam Walsh$19867.7% upsideOpen
2026-08-10Truist Financial$19565.2% upsideOpen
2026-08-07Morgan Stanley$21884.6% upsideOpen
2026-08-07Evercore ISI$17044% upsideOpen
2026-08-07Guggenheim$20573.6% upsideOpen
2026-08-07UBS$17245.7% upsideOpen
2026-08-07Wells Fargo$16943.1% upsideOpen
2026-08-06Jefferies$17548.2% upsideOpen
2026-07-28Cantor FitzgeraldOlivia Brayer$23599% upsideOpen
2026-07-20BMO CapitalConor MacKay$19262.6% upsideOpen
2026-07-20H.C. WainwrightAndrew Fein$22086.3% upsideOpen
2026-07-15Wells Fargo$16136.4% upsideOpen
2026-06-16Mizuho SecuritiesGraig Suvannavejh$19262.6% upsideOpen
2026-05-13Truist Financial$18556.7% upsideOpen
2026-05-08Wells Fargo$16035.5% upsideOpen
2026-05-08GuggenheimVamil Divan$22691.4% upsideOpen
2026-04-16Guggenheim$23094.8% upsideOpen
2026-04-14RBC Capital$21682.9% upsideOpen
2026-04-10Raymond James$20069.4% upsideOpen
2026-04-08Mizuho Securities$20271.1% upsideOpen
2026-03-26H.C. Wainwright$245107.5% upsideOpen
2026-02-24Mizuho Securities$20472.8% upsideOpen
2026-02-20Wells FargoTiago Fauth$20876.2% upsideOpen
2026-02-20Morgan Stanley$16640.6% upsideOpen
2026-02-19Stifel Nicolaus$20573.6% upsideOpen
2026-02-19Mizuho SecuritiesGraig Suvannavejh$21178.7% upsideOpen
2026-01-27BarclaysEliana Merle$23195.6% upsideOpen
2026-01-22Roth Capital$21279.6% upsideOpen
2026-01-21RBC CapitalLeonid Timashev$20069.4% upsideOpen
2026-01-12Truist FinancialDanielle Brill$20573.6% upsideOpen
2026-01-08Morgan StanleyMaxwell Skor$15733% upsideOpen
2026-01-06UBS$21582.1% upsideOpen
2025-12-19Truist FinancialDanielle Brill$20271.1% upsideOpen
2025-12-18H.C. Wainwright$23094.8% upsideOpen
2025-12-18Cowen & Co.$241104.1% upsideOpen
2025-12-18Mizuho SecuritiesGraig Suvannavejh$21279.6% upsideOpen
2025-12-18Guggenheim$22187.2% upsideOpen
2025-12-18Wedbush$20371.9% upsideOpen
2025-12-18RBC CapitalLeonid Timashev$19565.2% upsideOpen
2025-12-18Wells Fargo$19565.2% upsideOpen
2025-12-18Wolfe ResearchAndy Chen$16741.4% upsideOpen
2025-12-16Wells FargoTiago Fauth$23498.2% upsideOpen

Insmed (INSM) FAQ

Insmed (INSM) currently reports a target price of $190. Use the charts on this page to explore Insmed's target price history and peer comparisons.

Analysts' average 12-month price target for Insmed is $190, about 63.0% upside from the current share price of $118.07. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $190, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Insmed, and consider following INSM for alerts when major investors trade the stock.

Insmed is classified in the Healthcare sector. On target price, it currently shows $190. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing INSM with unrelated industries.